The therapy is expected to block abnormal blood vessel growth, limit vascular leakage, and reduce retina damage. The Food and Drug Administration (FDA) has granted Fast Track designation to SAR402663 ...

According to MingMed Biotechnology, 1 the QA102-CS201 trial enrolled 150 patients with intermediate atrophic AMD and randomly ...

Individuals in Taiwan who suffer from migraine were at an increased risk of developing neovascular age-related macular degeneration. Individuals suffering from migraine have a 20% increased risk of ...

In patients with a diagnosis of early- or intermediate-stage nonneovascular age-related macular degeneration (AMD), exposure to levodopa was associated with a significantly reduced risk for conversion ...

Neovascular AMD, while less common than its dry counterpart, causes nearly all cases of sudden, irreversible central vision loss due to abnormal blood vessel growth that damages the macula.

Please provide your email address to receive an email when new articles are posted on . Sozinibercept, a VEGF-C and -D “trap” inhibitor, showed improved durability in patients with retinal diseases ...

Please provide your email address to receive an email when new articles are posted on . ROME — A deep learning algorithm developed at University of California, Los Angeles, showed superior performance ...

—The findings about the diagnostic accuracy of the Amsler grid test for early detection of neovascular age-related macular degeneration suggest that the procedure will not replace regular ophthalmic ...

Three at-home vision-monitoring tools failed to detect worsening neovascular age-related macular degeneration (AMD), a diagnostic-test accuracy study reported. The paper-based KeepSight Journal from ...

In patients with neovascular age-related macular degeneration (nAMD), researchers found no clinically meaningful difference between treatment with the anti-VEGF agent aflibercept and the proposed ...